• 1
    Parkin DM,Bray F,Ferlay J,Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74108.
  • 2
    Levi F,Lucchini F,Negri E,La Vecchia C. Declining mortality from kidney cancer in Europe. Ann Oncol 2004; 15: 11305.
  • 3
    Motzer RJ,Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 56018.
  • 4
    Ravaud A,Wallerand H,Culine S,Bernhard JC,Fergelot P,Bensalah K,Patard JJ. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 2008; 54: 31525.
  • 5
    Latif F,Tory K,Gnarra J,Yao M,Duh FM,Orcutt ML,Stackhouse T,Kuzmin I,Modi W,Geil L. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 131720.
  • 6
    Uemura H,Nakagawa Y,Yoshida K,Saga S,Yoshikawa K,Hirao Y,Oosterwijk E. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999; 81: 7416.
  • 7
    Steffens MG,Boerman OC,Oosterwijk-Wakka JC,Oosterhof GO,Witjes JA,Koenders EB,Oyen WJ,Buijs WC,Debruyne FM,Corstens FH,Oosterwijk E. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997; 15: 152937.
  • 8
    Steffens MG,Boerman OC,de Mulder PH,Oyen WJ,Buijs WC,Witjes JA,van den Broek WJ,Oosterwijk-Wakka JC,Debruyne FM,Corstens FH,Oosterwijk E. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999; 5: s3268s74.
  • 9
    Davis ID,Wiseman GA,Lee FT,Gansen DN,Hopkins W,Papenfuss AT,Liu Z,Moynihan TJ,Croghan GA,Adjei AA,Hoffman EW,Ingle JN, et al. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun 2007; 7: 13.
  • 10
    Divgi CR,Pandit-Taskar N,Jungbluth AA,Reuter VE,Gonen M,Ruan S,Pierre C,Nagel A,Pryma DA,Humm J,Larson SM,Old LJ, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 2007; 8: 30410.
  • 11
    Bleumer I,Oosterwijk E,Oosterwijk-Wakka JC,Voller MC,Melchior S,Warnaar SO,Mala C,Beck J,Mulders PF. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol 2006; 175: 5762.
  • 12
    Davis ID,Liu Z,Saunders W,Lee FT,Spirkoska V,Hopkins W,Smyth FE,Chong G,Papenfuss AT,Chappell B,Poon A,Saunder TH, et al. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun 2007; 7: 14.
  • 13
    Bauer S,Adrian N,Williamson B,Panousis C,Fadle N,Smerd J,Fettah I,Scott AM,Pfreundschuh M,Renner C. Targeted bioactivity of membrane-anchored TNF by an antibody-derived TNF fusion protein. J Immunol 2004; 172: 39309.
  • 14
    Carswell EA,Old LJ,Kassel RL,Green S,Fiore N,Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 366670.
  • 15
    Creasey AA,Reynolds MT,Laird W. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res 1986; 46: 568790.
  • 16
    Dighe AS,Richards E,Old LJ,Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994; 1: 44756.
  • 17
    Muller-Hermelink N,Braumuller H,Pichler B,Wieder T,Mailhammer R,Schaak K,Ghoreschi K,Yazdi A,Haubner R,Sander CA,Mocikat R,Schwaiger M, et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008; 13: 50718.
  • 18
    Ikeda H,Old LJ,Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13: 95109.
  • 19
    Angiolillo AL,Sgadari C,Taub DD,Liao F,Farber JM,Maheshwari S,Kleinman HK,Reaman GH,Tosato G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995; 182: 15562.
  • 20
    Sgadari C,Angiolillo AL,Cherney BW,Pike SE,Farber JM,Koniaris LG,Vanguri P,Burd PR,Sheikh N,Gupta G,Teruya-Feldstein J,Tosato G. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci USA 1996; 93: 137916.
  • 21
    Schreiber RD,Hicks LJ,Celada A,Buchmeier NA,Gray PW. Monoclonal antibodies to murine gamma-interferon which differentially modulate macrophage activation and antiviral activity. J Immunol 1985; 134: 160918.
  • 22
    MacMicking J,Xie QW,Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15: 32350.
  • 23
    Shankaran V,Ikeda H,Bruce AT,White JM,Swanson PE,Old LJ,Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 110711.
  • 24
    Marincola FM,Jaffee EM,Hicklin DJ,Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181273.
  • 25
    Williamson BD,Carswell EA,Rubin BY,Prendergast JS,Old LJ. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA 1983; 80: 5397401.
  • 26
    Balkwill FR,Lee A,Aldam G,Moodie E,Thomas JA,Tavernier J,Fiers W. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res 1986; 46: 39903.
  • 27
    Ruegg C,Yilmaz A,Bieler G,Bamat J,Chaubert P,Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998; 4: 40814.
  • 28
    Sherman ML,Spriggs DR,Arthur KA,Imamura K,Frei E,III,Kufe DW. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol 1988; 6: 34450.
  • 29
    Nawroth PP,Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 7405.
  • 30
    Kilbourn RG,Gross SS,Jubran A,Adams J,Griffith OW,Levi R,Lodato RF. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990; 87: 362932.
  • 31
    Eggermont AM,ten Hagen TL. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. Curr Oncol Rep 2001; 3: 35967.
  • 32
    Lejeune FJ,Kroon BB,Di Filippo F,Hoekstra HJ,Santinami M,Lienard D,Eggermont AM. Isolated limb perfusion: the European experience. Surg Oncol Clin N Am 2001; 10: 82132, ix.
  • 33
    Bauer S,Adrian N,Fischer E,Kleber S,Stenner F,Wadle A,Fadle N,Zoellner A,Bernhardt R,Knuth A,Old LJ,Renner C. Structure-activity profiles of Ab-derived TNF fusion proteins. J Immunol 2006; 177: 242330.
  • 34
    Espevik T,Nissen-Meyer J. A highly sensitive cell line. WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 1986; 95: 99105.
  • 35
    Suk K,Chang I,Kim YH,Kim S,Kim JY,Kim H,Lee MS. Interferon gamma (IFNgamma) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNgamma inhibits cytoprotective. NF-kappa. B through. STAT1/IRF-1 pathways. J Biol Chem 2001; 276: 131539.
  • 36
    Steffens MG,Boerman OC,Oyen WJ,Kniest PH,Witjes JA,Oosterhof GO,van Leenders GJ,Debruyne FM,Corstens FH,Oosterwijk E. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy. Cancer Res 1999; 59: 161519.
  • 37
    Yilmaz A,Bieler G,Spertini O,Lejeune FJ,Ruegg C. Pulse treatment of human vascular endothelial cells with high doses of tumor necrosis factor and interferon-gamma results in simultaneous synergistic and reversible effects on proliferation and morphology. Int J Cancer 1998; 77: 5929.
  • 38
    van Schaijk FG,Oosterwijk E,Molkenboer-Kuenen JD,Soede AC,McBride BJ,Goldenberg DM,Oyen WJ,Corstens FH,Boerman OC. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J Nucl Med 2005; 46: 495501.
  • 39
    Thiry A,Dogne JM,Masereel B,Supuran CT. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 2006; 27: 56673.
  • 40
    Bakker WH,Krenning EP,Breeman WA,Koper JW,Kooij PP,Reubi JC,Klijn JG,Visser TJ,Docter R,Lamberts SW. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. J Nucl Med 1990; 31: 15019.
  • 41
    Shaw SK,Perkins BN,Lim YC,Liu Y,Nusrat A,Schnell FJ,Parkos CA,Luscinskas FW. Reduced expression of junctional adhesion molecule and platelet/endothelial cell adhesion molecule-1 (CD31) at human vascular endothelial junctions by cytokines tumor necrosis factor-alpha plus interferon-gamma does not reduce leukocyte transmigration under flow. Am J Pathol 2001; 159: 228191.
  • 42
    Lienard D,Eggermont AM,Koops HS,Kroon B,Towse G,Hiemstra S,Schmitz P,Clarke J,Steinmann G,Rosenkaimer F,Lejeune FJ. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9: 491502.
  • 43
    Furrer M,Altermatt HJ,Ris HB,Althaus U,Ruegg C,Lienard D,Lejeune FJ. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system. Melanoma Res 1997; 7( Suppl 2): S43S49.
  • 44
    Sacchi A,Gasparri A,Curnis F,Bellone M,Corti A. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res 2004; 64: 71505.
  • 45
    Curnis F,Gasparri A,Sacchi A,Cattaneo A,Magni F,Corti A. Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res 2005; 65: 290613.
  • 46
    Curnis F,Sacchi A,Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002; 110: 47582.
  • 47
    Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996; 7: 23140.
  • 48
    Lee JK,Sayers TJ,Brooks AD,Back TC,Young HA,Komschlies KL,Wigginton JM,Wiltrout RH. IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells. J Immunol 2000; 164: 2319.
  • 49
    Red-Horse K,Ferrara N. Imaging tumor angiogenesis. J Clin Invest 2006; 116: 25857.
  • 50
    Aulitzky WE,Aulitzky WK,Frick J,Herold M,Gastl G,Tilg H,Berger M,Huber C. Treatment of cancer patients with recombinant interferon-gamma induces release of endogenous tumor necrosis factor-alpha. Immunobiology 1990; 180: 38594.
  • 51
    Escudier B. Advanced renal cell carcinoma: current and emerging management strategies. Drugs 2007; 67: 125764.